Skip to content
Markets News
Stocks1 min read

Iovance reports 50% response rate in sarcoma cell-therapy study

Makkler Newsroom
October 26, 2026 · Based on reporting by GlobeNewswire

Four of eight evaluable patients had confirmed partial responses, all ongoing at the September data cutoff, the company said.

Key takeaways

  • Lifileucel produced a 50% confirmed response rate among eight evaluable patients.
  • All four partial responses were ongoing at the September 9 data cutoff.

Iovance Biotherapeutics said one-time lifileucel treatment produced a 50% confirmed response rate among the first eight evaluable patients in a pilot study of advanced soft tissue sarcomas.

The four partial responses, two in undifferentiated pleomorphic sarcoma and two in dedifferentiated liposarcoma, were all ongoing as of September 9. They had lasted at least 6, 26, 40 and 46 weeks, respectively. The company said the treatment’s safety profile was consistent with its use in other indications.

Iovance said its registrational Phase 2 SARATOGA trial is enrolling patients with the two cancers at Memorial Sloan Kettering Cancer Center and other major U.S. cancer centers.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.